Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	80135
Country	China

Received	2022-09-18 15:53
Peer-Review Started	2022-09-18 15:56
To Make the First Decision
Return for Revision	2023-02-04 06:37
Revised	2023-02-11 05:14
Second Decision	2023-02-24 03:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-02-28 00:46
Articles in Press	2023-02-28 00:46
Publication Fee Transferred
Edit the Manuscript by Language Editor	2023-03-06 02:26
Typeset the Manuscript	2023-03-07 04:54
Publish the Manuscript Online	2023-03-15 02:14

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Immunotherapy for advanced or recurrent hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Ying-Zhe Luo and Hong Zhu
Funding Agency and Grant Number	Funding Agency Grant Number The Key research projects of Science and Technology of Sichuan Province 2022YFS0189
Corresponding Author	Hong Zhu, MD, PhD, Associate Professor, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu 610041, Sichuan Province, China. 441695131@qq.com
Key Words	Recurrent hepatocellular carcinoma; Immunotherapy; Immune checkpoint inhibitor; Chimeric antigen receptor-engineered T cell; Oncolytic virus; Tumor vaccine
Core Tip	The high recurrence rate of hepatocellular carcinoma (HCC) following radical treatment remains challenging; therefore, immune checkpoint inhibitors (ICIs) are increasingly being used to treat HCC. Herein, we discuss the ICIs in practice and those undergoing trials, and summarize the alternative strategies such as chimeric antigen receptor-engineered T cell therapy and tumor vaccines. Combination therapy is also a promising potential treatment option. We believe our study significantly contributes to the literature as it addresses the current state of immunotherapy against HCC and provides insights into the advantages and limitations, thereby facilitating future research.
Publish Date	2023-03-15 02:14
Citation	Luo YZ, Zhu H. Immunotherapy for advanced or recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023;15(3): 405-424
URL	https://www.wjgnet.com/1948-5204/full/v15/i3/405.htm
DOI	https://dx.doi.org/10.4251/wjgo.v15.i3.405

Full Article (PDF)	WJGO-15-405.pdf
Full Article (Word)	WJGO-15-405.docx
Manuscript File	80135-Review-FilipodiaCL.docx
Answering Reviewers	80135-Answering reviewers.pdf
Audio Core Tip	80135-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	80135-Conflict-of-interest statement.pdf
Copyright License Agreement	80135-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	80135-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	80135-Language certificate.pdf
Peer-review Report	80135-Peer-review(s).pdf
Scientific Misconduct Check	80135-Bing-Fan JR-2.png
Scientific Editor Work List	80135-Scientific editor work list.pdf